fda compounding semaglutide crackdown news today The announced plans to take action against non-FDA-approved GLP-1 receptor agonists, a move that prompted telehealth company Hims & Hers to yank its new compounded (Wegovy) weight-loss pill from the Maybe i’m not against compounding
Description
Theres no direct semaglutide to tirzepatide conversion
In other words, while recognising obesity as a chronic disease might reduce weight stigma, using pharmacological approaches alone for obesity management could shift the emphasis away from an overhaul of the current obesogenic food environment that encourages overconsumption
In addition to needing long-term data in primary CV prevention populations, further research evaluating the CV effects of other GLP-1RA and SGLT2-I is required to understand whether such findings are agent or dose dependent
R.BourdetD
Whats driving this increase
*The recommended duration of use is 3 months
